PharmExec CEO Roundtable: Retaining the Changed Workforce
Among the topic discussed at the roundtable were ways to address acquiring and attracting new talent, as well as retaining talent in the post-COVID workforce.
Please read the full article Ready for Pharma's Next Chapter about Trends for 2022.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
May 7th 2025Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
